India Strikes Pricing Blow To Knees After Stent Cuts
Executive Summary
Six months after imposing stiff price controls on cardiac stents, India’s government slashed costs of knee implants by nearly 70%, saying the action was necessary to end “unethical profiteering.”
You may also be interested in...
Multinational Medtech Firms Accuse Indian Peers Of Exaggerating Imports In Bid For Higher Duties
Global medical device manufacturers have accused their Indian counterparts of exaggerating medtech import numbers to get the government to hike import duties and shield them from foreign competition.
FDI In India’s Medical Devices Sector Plunges, Experts Blame Price Controls
FDI in India's medtech sector has plunged to levels last seen before investment in the sector was liberalized and the Indian association representing global medical technology firms says government-imposed price controls are to blame.
India-US Tensions Grow In Device Pricing Cap Controversy
India's price capping for medical devices is threatening to snowball into a trade tit-for-tat with the US. The US Trade Representative is intervening on the matter at the behest of industry. While a middle path is probably still possible, pro-health groups in India have decried the “reprehensible” US move, and others are suggesting a tax on US luxury goods should the issue escalate.